Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Resectable Merkel Cell Carcinoma
NCT05496036Phase 2Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Merkel cell carcinoma (MCC), sponsored by Abramson Cancer Center. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT05496036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496036.